Introduction
Malaria, with AIDS and tuberculosis, is one of the three major communicable diseases linked to poverty. The unavailability of a vaccine and the spread and intensification of drug resistance over the past [15] [16] [17] [18] [19] [20] years have led to a dramatic decline in the efficacy of the most affordable antimalarial drugs. [1] [2] [3] In order to circumvent that situation, medications based on the association of two substances acting against the parasite have been developed.
The basis of this study was to develop new compounds acting through distinct mechanisms during both the liver stage and the blood stage of the life cycle of the parasite. Compounds were designed on the basis of the "double-drug" approach: primaquine (PQ a ), active against the gametocytes and hypnozoites of the relapsing malaria parasites P. ViVax and P. oVale and which has been linked to statine-based inhibitors of plasmepsins (PLMs), the aspartic proteases involved in degradation of hemoglobin during the blood stage of the parasite. 4 The therapy with PQ has been reconsidered after the observation that PQ is a safe and effective agent for the prophylaxis of malaria due to both P. falciparum and P. ViVax. 5 Furthermore, the use of the prodrug Val-Leu-Lys-PQ reduced toxicity and increased the activity of the drug. 6 Several inhibitors of PLM II have already been designed by replacement of the scissile peptide bond with a transition state analogue, 7, 8 including PS777621 characterized by a statine-based core ( Figure 1 ). 9 A drawback for the development of substratebased PLM II inhibitors was that while enzyme inhibition occurred at the nanomolar level, effectiveness of the inhibitors in killing the parasite was limited (IC 50 ) 2-20 µM). [9] [10] [11] Differences of this kind were attributed to low bioavailability probably because most of these inhibitors are derived from peptides. However, in view of recent publications, the low potency against cultured parasites may also be explained by the plasmepsins' redundancy, 12, 13 which implies that blockade of this enzyme family may not be lethal. 14 The "double-drug" strategy might help to improve cell permeability and pharmacological activity while reducing dose and side effects. Following this strategy, we published the antiplasmodial activity of a series of compounds that have a statine moiety bound to Leu-Lys-PQ residue by means of different linkers. 15 The best IC 50 value for the inhibition of P. falciparum was 0.4 µM, thus achieving a remarkable improvement with respect to other inhibitors of PLM II. [8] [9] [10] [11] We also demonstrated that the removal of the Lys-PQ moiety led to a drastic reduction of the antiparasitic activity.
In this paper we report the synthesis and the biological evaluation of nine new statine-based PLMs inhibitors (Table  1) . Our efforts were mainly directed in improving the killing on the parasite during the intraerythrocytic stage. All synthesized compounds presented the statine moiety unchanged, while modifications were made to the Leu-Lys-PQ unit (Table 1 ). In particular, the first variations were directed toward the dipeptide Leu-Lys by removing Lys (2) or both amino acids (3) . In compounds 4-8 the Leu-Lys dipeptide has been modified by introducing Ala in place of the Lys and/or Leu residue or by protecting the N of Lys with a Boc group. In compounds 9 and 10 the PQ residue has been substituted with a propyl ester and the N of Lys was unsubstituted or protected with a Boc group.
The compounds have been tested in vitro against recombinant PLMs I and II, and against D10 (chloroquine sensitive) and W2 (chloroquine resistant) strains of P. falciparum, using compound 1 (representing the previously described PS777621) as the reference molecule. The selectivity over human cathepsin D, which shares a high homology with PLMs, and cell toxicity on mammalian cells were also investigated for the most promising compounds.
Results
Chemistry. In view of the high costs of commercially available statine, a gram-scale synthesis of N-Boc-statine has been developed in order to obtain compounds 1-10 (Schemes 1 and 2). Stereoselective addition of the zinc enolate of ethylacetate 16 to N-Boc-leucinal 17 resulted in N-Boc-statine ethyl ester 11, which after hydrolysis and coupling with butylamine followed by Boc removal and coupling with BocIleOH gave intermediate 12, easily purified by crystallization. This synthesis required only one chromatographic purification step (after enolate addition), and the overall yields from Boc-leucine were 15%. After deprotection of 12 to give amine 13 and coupling with the monobenzyl ester of 4,4′-oxybisbenzoic acid 14, obtained by selective monobenzylation of 4,4′-oxybisbenzoic acid, compound 15, the statine-containing portion of inhibitors 3-8, was obtained (Scheme 1). The PQ-containing portions, 18-22, of inhibitors 4-8 were obtained by reaction of PQ diphosphate with Boc-leucine or Boc-alanine using standard coupling conditions to give compounds 16 and 17, which were coupled to Cbz-leucine or Cbz-alanine to give PQ-containing fragments 18-20. Lysine-containing fragments 21 and 22 were obtained by coupling with 4′-N-(N -Boc-lysyl)PQ 6 (Scheme 1).
The PQ-containing fragments 18-20 and 22 and the statinecontaining fragment 15 were simultaneously deprotected and coupled to afford final compounds 5-8. Compound 3 was obtained by coupling of 15 with PQ and compound 4 by coupling of 15 with 21 followed by deprotection of the lysine N Boc group and formation of the diphosphate salt (Scheme 1). For the synthesis of 2 a slightly different synthetic approach was undertaken (Scheme 2). The monobenzyl ester of 4,4′-oxybis(benzoic acid) 14 was first coupled to 4′-N-(Boc-leucyl)-PQ 17 and subsequently coupled with the statine-containing fragment 13.
The synthesis of compounds 1, 9, and 10, not containing PQ, was carried out as described in Scheme 2. Compound 1 was prepared by coupling 2-naphthoxyacetic acid to 13. Fully protected lysine derivative 25 was prepared by N Boc protection of Cbz-lysine allyl ester, 18 which was coupled with Cbz-leucine to give compound 26, followed by coupling with the monobenzyl ester of 4,4′-oxybis(benzoic acid) 14 to give dipeptide intermediate 27, which was coupled to statine salt 13 to give compound 10. Compound 9 was prepared by N Boc deprotection of 10.
Effect of Compounds on PLM I and PLM II Activities. All compounds inhibited both PLM I and PLM II in a concentration-dependent fashion (Table 1) . PLM I inhibition was improved in comparison to 1 for all the compounds with the exception of compound 2. In particular, compound 2, deprived of Ala, and compound 7, where the N of Lys is Bocprotected, possessed the lowest affinity for PLM I (K i of 765 and 230 nM, respectively). For compounds 2-6, K i values for PLM II inhibition ranged between 4 and 26 nM, which represents an improvement with respect to 1, while for 7 and 8 the affinity decreased. Compounds 9 and 10 showed similar values for inhibition of PLMs I and II, (K i ) 10-17 nM). Compound 5 deserves particular attention in view of the highest inhibition against both PLMs (1.0 and 3.9 nM for PLM I and PLM II, respectively), demonstrating a remarkable improvement toward PLM I (>700-fold vs 1).
As assessed by SDS-PAGE (Figure 2 ), compounds 2, 6, and 10, the best inhibitors of the parasite growth (Table 1) , were able to prevent the human hemoglobin cleavage induced by PLM II, a result that further supports the possibility that these molecules are able to inhibit the enzyme when hemoglobin is the substrate for P. falciparum PLMs.
Effect of Compounds on P. falciparum Growth. All PQstatine compounds inhibited parasite growth in a dose-dependent manner, and IC 50 values against both strains (0.2-4 µM) are significantly below that of the reference compound 1 (15-23 µM) , confirming that the "double-drug" approach represents a good strategy for improving the effectiveness of PLM inhibitors to starve and kill the parasite. By comparison of compounds 4-8 characterized by a dipeptide linking PQ to the statine portion of the molecule, compound 6 with the Leu-Ala dipeptide was found to be the most active compound against both D10 chloroquine-sensitive and W2 chloroquine-resistant strains of P. falciparum (0.2 and 0.3 µM, respectively). Modifications at the Leu-Ala dipeptide decreased the antiplasmodial activity (4, 5, 7, 8). While compound 2 showed a lower activity against the D10 strain than compound 6 and while the effect on W2 was comparable, compound 3 showed a sharp decrease in activity against both strains. In our previous study 15 we demonstrated that the removal of aminoquinoline led to a dramatic loss of inhibitory activity, while, as shown here, compound 10, where PQ is replaced by a propyl ester group and the amino group of Lys is protected, still maintains a very high inhibitory activity (IC 50 ) 0.1 µM). For compound 9, where the amino group of Lys is not Boc-protected, the killing effect worsened (IC 50 ) 3.8-4.5 µM).
Molecular Modeling. The 3D structural models of compound 6, one of the most promising compounds, were constructed from pepstatin A using the X-ray crystal coordinates of pepstatin A in complex with plasmepsin II (PDB entry 1XDH) as a starting point. Figure 3 shows a superimposition of the conformers of 6 with pepstatin A, while the conformers of 6, without pepstatin A, in complex with PLM II are shown in Figure 4 . Molecular modeling shows that the side chains of Ile and Sta and the N-butylammido group are easily superimposed with pepstatin A (Figure 3 ) and are nicely accommodated within the active site ( Figure 4) . The conformational freedom of the 4,4′-oxybisbenzoic ring system allows the LeuAla-PQ part of the molecule to assume several conformations in which PQ is partially or totally exposed to the solvent (Figure 4 ). PQ does have a great deal of conformational freedom in the active site, and since it is exposed to the solvent, it is quite difficult to predict an active conformation. The model shows that the enzyme is easily able to accommodate large substituents after P3 and the 4,4′-oxybisbenzoic ring system is fitted nicely within the active site.
Correlation between Lipophilicity (log P) and Biological Activities. To verify whether lipophilicity and therefore cell penetration was correlated to the antiparasite activity, the degree of lipophilicity expressed as the log P value of PLM inhibitors was plotted against the ratio of the IC 50 against the P. falciparum W2 strain in RBCs to the IC 50 against PLM II ( Figure 5 ). The log P values were calculated using the Accelrys DS ViewerPro 5.0 property calculator (trial version) and are indicated as ALogP. The ratio of the IC 50 values was chosen as an indicator of cell penetration of the synthesized inhibitors; the number will increase along with the impairment to cross cell membranes. A linear correlation (r ) 0.86) between lipophilicity and activity ratio was obtained for all compounds but one (9) .
Selectivity toward Human Cathepsin D and Cytotoxicity. For compounds 2, 6, and 10, cathepsin D inhibition was negligible at the concentration required to inhibit PLM II by 50% (IC 50 ) (data not shown). At concentrations 100-fold higher, cathepsin D was inhibited by 30%, 50%, and 37%, respectively (Table 1) , indicating a good selectivity for the plasmodial enzyme. Similarly, no antiproliferative activity was found when human skin fibroblasts were cultured in the presence of the compounds at concentrations as high as 100 µM. These results support for a negligible cytotoxic effect on mammalian cells at concentrations necessary to kill the parasite (below 1 µM).
Discussion
The PQ-statine compounds examined in this study represent the evolution of the first series of statine-based PLM II inhibitors designed by following the double-drug approach as devised by Romeo et al. 15 In agreement with previous results, it is confirmed that with this approach we have synthesized PLM II inhibitors that are much more active on P. falciparum than 1 (PS777621) and other transition state analogue inhibitors previously reported. [9] [10] [11] Considering the redundancy of PLMs, 12, 13 it is therefore necessary to design compounds able to inhibit two or more in this enzyme family in order to develop drugs active on P. falciparum. Some of the synthesized compounds, designed as PLM II inhibitors, are also strong inhibitors of PLM I, which is, in view of the recent literature, a prerequisite for developing new antimalarial agents. 13, 14 In this regard, work is in progress to demonstrate the ability of PQ-statine inhibitors to block PLM IV and the orthologues from P. malariae, P. oVale, and P. ViVax (manuscript in preparation).
By comparison of the PLM I inhibitory activity of the reference compound 1 with the effect exerted by compounds 2-10, it is evident that most of them showed a remarkable improvement of activity. In particular the presence of the dipeptide influences the affinity for PLM I to a greater extent than PLM II with a preference for the Ala-Ala dipeptide (5), which shows an 80-fold improvement compared to compound 3, which lacks the dipeptide linker.
It is noteworthy that most of the tested compounds possess an anti-PLM II activity much greater than compound 1. With the exclusion of compounds 7 and 8, any change to the peptide chain linking the PQ group to the 4,4′-oxybisbenzoic ring or the substitution of PQ with a propyl ester group did not bear heavy changes of PLM II K i values ( Table 1 ), indicating that PQ is not essential for PLM II inhibition. From modeling studies it looks like most of the conformations show solvent-exposed PQ and lack of interactions of the dipeptide linker with the enzyme. If this is true, no significant score differences will be seen because the score function mainly evaluates the interactions in the assigned boxes, i.e., in the active site cleft. Thus, structural modifications of this part of the molecule should not greatly affect the PLM II K i values of the compounds. Regarding compounds 7 and 8, which have the lowest affinity for PLM II, their interaction with the enzyme may be impaired by their high lipophilicity as deduced from the ALogP values ( Figure  5 ).
The inhibition of P. falciparum growth in the erythrocytes was drastically improved by all compounds in comparison to 1. IC 50 values were below 1 µΜ for compounds 2, 4, 6, and 10 with a noteworthy value of 100 nM for compound 10, which represents the most active transition state analogue inhibitor to the best of our knowledge. Furthermore the PQ-statine compounds are equally active against chloroquine-sensitive and chloroquine-resistant strains of P. falciparum, thus suggesting that the mechanism of action (i.e., PLM inhibition) and the mechanism for chloroquine resistance are independent.
The degree of PLM inhibition is not predictive of the ability to kill the parasite, since compounds with K i values of 1-700 nM possess a range of potency against the parasite, falling within a much narrower interval (IC 50 values of 0.1-4 µM). If parasite growth is not always correlated to PLM inhibition, then several factors could contribute to the antiplasmodial activity of these compounds and help explain the lack of correlation with inhibition of PLMs. They include (i) the ability to penetrate the cell and the food vacuole, where hemoglobin is degraded by PLMs I and II and (ii) the blockage of other proteolytic enzymes working in combination with PLM impairment.
In general, the crossing of cell membranes by a drug is facilitated by the hydrophobicity of the molecule. Figure 5 clearly shows that a linear correlation exists between log P values and the ratio of potencies against parasite and affinities against PLM II, thus indicating that PLMs are the main target of these compounds in the parasite. These results indicate that a good balance between inhibitory activity and lipophilicity is required in order to achieve efficacy in the cell.
The log P data indicate that for the compounds described here this rule is true for all but one (9). Compound 9 might undergo biotransformation, reducing its lipophilicity and thus interfering with cell bioavailability. We have previously shown that the breakdown of Lys-Xaa releases fragments much less potent than the parent compounds. 15 The difference of the order of magnitude between enzymatic K i and cell potency (IC 50 ) ranged between 10-and 400-fold. In light of the recent paper by Liu et al., 14 it appears that bioavailability is not a limitation for killing cultured parasites, since pepstatin A was able to enter the food vacuole. Then it is possible that the potency of the compounds described is determined not only by their bioavailability but rather by the possibility that they inhibit not only plasmepsins but also other proteolytic enzymes (such as the falcipains).
The most promising inhibitors of P. falciparum growth (2, 6, 10) showed only negligible or no cytoxicity when tested on human fibroblasts cell line, indicating that these compounds interfere with mechanisms unique for the parasite; this observation was confirmed by the high selectivity of these compounds for PLMs in comparison to human cathepsin D.
The compounds under study, which have been designed on the basis of the double-drug approach, contain PQ, which is a drug active against liver-stage malaria parasites. Thus, compounds 2-8 containing PQ could also exert an inhibitory effect on this stage in addition to the intraerythrocytic effect. The in vivo studies should elucidate this hypothesis. In conclusion, the evidence that some of the inhibitors reported possess very good efficacy against P. falciparum growth and a great selectivity in comparison to other inhibitors reported in the literature (0.1 vs 2-20 µM) [19] [20] [21] makes these novel compounds very promising for further development as antimalarial agents.
Experimental Section
Expression of Recombinant PLMs I and II. PLM I preparation will be described in full (Liu et al., manuscript in preparation) . Briefly, expression of the recombinant proPfPLM I was induced at 37°C in the BL21 Star (DE3) pLysS E. coli using 1 mM IPTG. After 3 h of induction, cell pellets were harvested and inclusion bodies were extracted and purified according to the procedure previously described. 22 Inclusion body materials were solubilized in 6 M urea, 50 mM sodium phosphate, pH 8.5, and 500 mM sodium chloride. Protein was refolded by dialysis against 20 mM Tris-HCl, pH 8.0, and further purified by anion exchange and size exclusion chromatography.
PLM II was prepared according to the procedure previously described, 23 with slight modifications. Briefly, pET-3a expression plasmid containing PLM II precursor gene was transformed into BL21-(DE3) pLysS E. coli. A single colony was used to inoculate 100 mL of LB medium. The culture was grown overnight at 30°C
, and an amount of 60 mL was used to inoculate 3 L of fresh LB. Cells were grown until the OD at 600 nm reached 0.4. They were then induced with IPTG at a final concentration of 1 mM. After a further 3 h of incubation, cells were harvested by centrifugation and resuspended in 100 mM Tris-HCl, pH 8, containing 0.2% Triton. After the addition of lysozyme (1 mg/mL), resuspended cells were incubated at 37°C for 30 min. The volume was sonicated. Then solid urea was added to reach a final concentration of 500 mM and the solution was stirred at room temperature for 30 min. Inclusion bodies were harvested by centrifugation at 16000g for 10 min and then resuspended in the same buffer, stirred for 30 min, and spun as before. Inclusion bodies were solubilized in 6 M urea, 100 mM Tris-HCl, pH 8.5, and 32 mM -mercaptoethanol. Protein was refolded by dialysis against 10 L of 10 mM Tris-HCl, pH 8.5. Protein concentration was determined according to the method of Bradford. 24 Protein was diluted to a final concentration of 0.5 mg/mL in 50% glycerol and stored at -20°C.
Enzyme Inhibition Assays. PLM I Assay. For a tight binding (K i ) 50 pM to 10 nM) competitive inhibitor, the initial rates (AU/ s) of enzymatic cleavage of a chromogenic peptide substrate (LysPro-Ile-Leu-Phe-Nph-Arg-Leu) of known concentration (µM) in the presence of different concentrations (nM) of inhibitors were measured using a Cary 50 spectrophotometer (Varian). 22 The K PLM II Assay. Pro-PLM II was activated by addition of onetenth volume of 100 mM sodium acetate buffer, pH 4.7, followed by incubation at 37°C for 90 min. The enzyme activity of PLM II was evaluated spectrophotometrically at 300 nm by following the cleavage of the chromogenic substrate Lys-Glu-Phe-Val-Phe-NPheAla-Leu-Lys (where NPhe is p-nitrophenylalanine), as described. 23 Inhibitors were tested at 1-100 nM dissolved in DMSO (final concentration of 1% of the sample volume). IC 50 values were obtained using Graph Pad Prism 4. The K i values for PLM II were subsequently calculated by using and a K m value determined according to Michaelis-Menten. Results are expressed as the mean ( standard deviation of at least two separate experiments performed in triplicate.
Cathepsin D Assay. Human liver cathepsin D was purchased from Sigma-Aldrich, Milan, Italy. The enzyme activity was measured as described for PLM II by incubating 0.714 U of protein with 27 µg of substrate in 100 mM sodium acetate buffer, pH 4.7. Final incubation volume was 0.6 mL. The compounds were tested against cathepsin D at concentrations 100-fold higher than that required to inhibit PLM II by 50% (IC 50 ).
Parasite Growth. The CQ-sensitive (D10) and the CQ-resistant (W2) strains of P. falciparum were sustained in vitro as described by Trager and Jensen. 25 Parasites were maintained at 5% hematocrit (human type A-positive red blood cells) in RPMI 1640 (Gibco BRL, NaHCO 3 24 mM) medium with the addition of 10% heat-inactivated A-positive human plasma, 20 mM Hepes (Euroclone), and 2 mM glutammine (Euroclone). All cultures were maintained at 37°C in a standard gas mixture consisting of 1% O 2 , 5% CO 2 , 94% N 2 .
Drug Susceptibility Assay on P. falciparum. Compounds were dissolved in either water (chloroquine) or DMSO and then diluted with a medium to achieve the required concentrations (final DMSO concentration of <1%, which is nontoxic to the parasite). Drugs were placed in 96-well flat-bottom microplates (COSTAR), and serial dilutions were made. Asynchronous cultures with parasitemia of 1-1.5% and 1% final hematocrit were aliquoted into the plates and incubated for 72 h at 37°C. Parasite growth was determined spectrophotometrically (OD 650 ) by measuring the activity of the parasite lactate dehydrogenase (LDH) according to a modified version of Makler's method in control and drug-treated cultures. 26 Antiplasmodial activity is expressed as the 50% inhibitory concentrations (IC 50 ). Each IC 50 value is the mean ( standard deviation of at least three separate experiments performed in duplicate.
Hemoglobin Degradation Assay by PLM II in the Presence of PQ-Statine Compounds. The ability of the most active compounds to prevent the hemoglobin degradation by PLM II was assayed by SDS-PAGE. 27 Briefly, hemoglobin (10 µg) was incubated with preactivated PLM II (200 ng) at 37°C, pH 4.7, in a final digest volume of 16 µL of 100 mM sodium acetate buffer and in the presence of the vehicle or the PLM II inhibitor for 10, 30, and 60 min. The reaction was stopped by the addition of SDS loading dye. Samples were denatured by boiling for 5 min and loaded onto 18% polyacrylamide gel.
Cytotoxicity Assay. Cytotoxicity was evaluated in human fibroblasts from skin biopsies. Fibroblasts (8 × 10 4 per well) were grown in 24-well plates with DMEM containing 10% fetal calf serum, 1% penicillin/streptomycin, and 1% L-glutamine as previously described. 28 Cell proliferation was followed by the MTT (3- 29 in the absence or in the presence of the tested compounds (up to 100 µM).
Modeling of PLM II with PQ-Statine Inhibitors.
The 3D structural models of compound 6, one of the most promising compounds (Table 1) , were constructed from pepstatin A using the X-ray crystal coordinates of pepstatin A in complex with plasmepsin II (PDB entry 1XDH) as a starting point. The Val residue in P2 of pepstatin A was changed in Ile and substituted with 4,4′-oxybisbenzoic acid. The C-terminal residues AlaSta of pepstatin A were removed, and the n-butylamine chain was added. This molecule was minimized within the active site allowing all atoms to move, while the enzyme was kept fixed. The LeuAlaPQ part of the molecule was separately built and minimized in an extended conformation. The two parts of 6 were then joined and minimized in the active site as previously described. Conformers of 6 were manually generated by rotating the bonds of the 4,4′-oxybisbenzoic ring system while leaving the LeuAlaPQ part of the molecule fixed. Each conformer was minimized within the PLM II allowing all atoms of 6 to move, while the enzyme was kept fixed. The minimizations were performed in Accelrys DS ViewerPro 5.0 Conformer (trial version) with the steepest descent. All minimizations converged before 10 000 iterations.
General Methods. NMR spectra were recorded on a Varian 300 MHz instrument using CDCl 3 , CD 3 OD, or DMSO-d 6 as solvents. TMS was used as reference. Peaks were assigned with 2D COSY experiments and are consistent with the proposed structures. Melting points were determined with a Büchi apparatus and are uncorrected. TLC was carried out on Merck precoated 60 F254 plates using UV light and dipping with ethanol/phosphomolybdic acid (10%) or a solution of 0.5% ninhydrin in ethanol for visualization. Flash column chromatography was performed using silica gel 60 (0.040-0.063 mm, Merck). Organic phases were dried over anhydrous sodium sulfate. Concentrations were performed under diminished pressure (1-2 kPa) at a bath temperature of 40°C. High-resolution mass spectra (ESI) were recorded on a Fourier transform ion cyclotron resonance mass spectrometer APEX II and Xmass software (Bruker Daltonics). Mass spectra (ESI, positive ions) were recorded on a LCG Advantage (Thermo Finnigan).
General Synthetic Procedures. Procedure A. Coupling. The carboxylic acid (1.1 equiv) and the amine (1.0 equiv) are dissolved under nitrogen in an appropriate solvent (DMF, dichloromethane, or acetonitrile) (5 mL/mmol). N-Methylmorpholine was then added followed by hydroxybenzotriazole solution (HOBt) (1.5 equiv). The resulting solution was cooled at 0°C, and O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU) was added (1.1 equiv). The mixture was then stirred at room temperature overnight. Dichloromethane was then added, and the organic phase was washed with citric acid (5%), saturated NaHCO 3 , water, and brine, dried, filtered, and concentrated.
General Synthetic Procedures. Procedure B. Removal of the Boc Group (HCl). After cooling the Boc-protected compound at 0°C, 4 N HCl in dioxane was added (1 mL/100 mg of compound). The mixture was stirred at room temperature for 30 min. After this time the mixture was concentrated and the residue washed three times with ethyl ether and used in the next step without any further purification or characterization.
General Synthetic Procedures. Procedure C. Removal of the Boc Group (TFA). To the Boc-protected compound was added dropwise at room temperature a 1:1 solution of TFA/dichloromethane (4 mL/mmol). After being stirred for 40-50 min, the mixture was concentrated and washed three times with ethyl ether and filtered, and the solid obtained was used in the next step without any further purification or characterization.
General Synthetic Procedures. Procedure D. Removal of the Cbz Group by Catalytic Hydrogenation. The Cbz-protected compound was dissolved in methanol (10 mL/mmol), and then Pd/C (80 mg/mmol) added. When the reaction was completed (30-40 min), the mixture was filtered and washed with methanol and the residue was concentrated and used in the next step without any further purification or characterization. (3S,4S)-4-(tert-Butoxycarbonylamino)-3-hydroxy-6 -methylheptanoic Acid Ethyl Ester (BocStaOEt) (11). Anhydrous THF (24 mL) and LDA (2 N, 28.3 mL, 56.6 mmol) were cooled under nitrogen atmosphere at -80°C. Ethyl acetate (5.6 mL, 56.6 mmol) was then added followed by a 0°C solution of anhydrous ZnBr 2 (12.7 g, 56.6 mmol) in anhydrous THF (24 mL). A -78°C solution of Boc-leucinal 17 (1.81 g, 8.4 mmol) in anhydrous THF (6 mL) was then added, and the mixture was stirred at -78°C for 10 min and finally allowed to reach room temperature overnight. After the reaction mixture was cooled at 0°C, 25 mL of a solution of aqueous saturated NH 4 Cl and acetic acid (9:1) was added and extracted with cooled ethyl ether (four times). The organic phase was washed with 1 N HCl (2 times) and with brine, dried over sodium sulfate, filtered, and concentrated under vacuum. The brownish oil was purified by silica gel chromatography (cyclohexane/ethyl acetate (90:10, 85: 15, 70:30) to give 11 as a white solid (253 mg, 0.84 mmol, 10%). 1 H 9 ) (12) . A solution of 2 N NaOH (0.84 mmol, 0.42 mL) was added dropwise to a solution of BocStaOEt (253 mg, 0.84 mmol) in dioxane/water (3:1, 6 mL) cooled to 0°C. The mixture was stirred at room temperature for 1.5 h. After completion, the reaction mixture was cooled to 0°C and cooled 2 N HCl was added until acidic pH was attained. Dioxane was removed by evaporation, and the aqueous phase was extracted with dichloromethane (three times). The organic phases were dried and concentrated, and the product was reacted with butylamine (61.4 mg, 0.84 mmol) under general procedure A. The reaction mixture was extracted with ethyl acetate, dried, and concentrated to give a crude product (195 mg), which was used without any further purification in the next reaction.
The crude product was reacted under general procedure B, followed by reaction under general procedure A with BocIleOH (194 mg, 0.84 mmol) to give after crystallization with ethyl acetate product 12 (257 mg, 0.58 mmol, 32%). 00 (12H, m), 1.03 (3H, d, J ) 6.66 Hz), 1.12-1.74 (9H, m), 2.03 (1H, m), 2.29 (1H, dd, J (4′-N-[Cbz-alanyl(N E -Boc-lysyl) -1-(4-(6-methoxyquinolin-8-ylamino)pentylamino)-1-oxohexan-2-ylamino)-1- 
